CDMO Avid Bioservices Inc

Price (delayed)

$4.995

Market cap

$315.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

$478.95M

Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a ...

Highlights
CDMO's revenue is up by 20% year-on-year
Avid Bioservices's equity has increased by 6% YoY
CDMO's net income has dropped by 103% year-on-year
The company's EPS has shrunk by 102% YoY

Key stats

What are the main financial stats of CDMO
Market
Shares outstanding
63.11M
Market cap
$315.25M
Enterprise value
$478.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.64
Price to sales (P/S)
2.09
EV/EBIT
N/A
EV/EBITDA
58.54
EV/Sales
3.19
Earnings
Revenue
$150.3M
EBIT
-$87,000
EBITDA
$8.18M
Free cash flow
-$92.96M
Per share
EPS
-$0.04
Free cash flow per share
-$1.48
Book value per share
$3.04
Revenue per share
$2.39
TBVPS
$7.04
Balance sheet
Total assets
$442.34M
Total liabilities
$251.74M
Debt
$188.94M
Equity
$190.6M
Working capital
$34.26M
Liquidity
Debt to equity
0.99
Current ratio
1.53
Quick ratio
0.65
Net debt/EBITDA
20.01
Margins
EBITDA margin
5.4%
Gross margin
17.6%
Net margin
-2.1%
Operating margin
-0.9%
Efficiency
Return on assets
-0.7%
Return on equity
-1.7%
Return on invested capital
0%
Return on capital employed
0%
Return on sales
-0.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDMO stock price

How has the Avid Bioservices stock price performed over time
Intraday
-1.87%
1 week
-9.02%
1 month
-14.62%
1 year
-68.35%
YTD
-63.73%
QTD
-47.09%

Financial performance

How have Avid Bioservices's revenue and profit performed over time
Revenue
$150.3M
Gross profit
$26.46M
Operating income
-$1.3M
Net income
-$3.1M
Gross margin
17.6%
Net margin
-2.1%
The operating margin has dropped by 138% since the previous quarter and by 110% year-on-year
The operating income has plunged by 136% from the previous quarter and by 112% YoY
CDMO's net income has dropped by 103% year-on-year
The company's net margin has shrunk by 102% YoY

Growth

What is Avid Bioservices's growth rate over time

Valuation

What is Avid Bioservices stock price valuation
P/E
N/A
P/B
1.64
P/S
2.09
EV/EBIT
N/A
EV/EBITDA
58.54
EV/Sales
3.19
The company's EPS has shrunk by 102% YoY
CDMO's price to book (P/B) is 85% less than its 5-year quarterly average of 10.9 and 68% less than its last 4 quarters average of 5.3
Avid Bioservices's equity has increased by 6% YoY
CDMO's P/S is 74% below its 5-year quarterly average of 8.2 and 69% below its last 4 quarters average of 6.9
CDMO's revenue is up by 20% year-on-year

Efficiency

How efficient is Avid Bioservices business performance
The company's return on sales has shrunk by 103% QoQ and by 101% YoY
The return on assets has dropped by 102% year-on-year
CDMO's return on equity has dropped by 102% year-on-year
Avid Bioservices's return on invested capital has shrunk by 100% QoQ and by 100% YoY

Dividends

What is CDMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDMO.

Financial health

How did Avid Bioservices financials performed over time
The total assets is 76% greater than the total liabilities
Avid Bioservices's quick ratio has plunged by 57% YoY and by 17% from the previous quarter
CDMO's current ratio is down by 21% year-on-year
Avid Bioservices's equity has increased by 6% YoY
The company's debt rose by 3.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.